CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)
Key claim: A first-in-human phase 1/1b study is evaluating the safety and preliminary efficacy of CER-1236 in patients with relapsed/refractory or MRD-positive AML, MDS, and myelofibrosis, including TP53-mutated disease.
Abstract
This is a first in human, multi center, open label, phase 1/1b study to evaluate the safety and preliminary efficacy of CER-1236 in patients with relapsed/refractory (R/R), measurable residual disease (MRD) positive acute myeloid leukemia (AML), or TP53mut disease.
Why this matters
CER-1236 represents a first-in-human investigational agent simultaneously targeting MF, MDS, and AML — including the historically refractory TP53-mutated subset — and thus addresses a high-unmet-need population that crosses the PMF/MDS-MPN-overlap/post-MPN-AML boundary. Co-enrollment of these subtypes in a single trial reinforces a shared advanced-myeloid-neoplasm therapeutic frontier where transformation risk and TP53 biology dominate prognosis. Tracking CER-1236’s mechanism and early signals will help clarify whether it offers subtype-agnostic activity or differential benefit across PMF versus dysplastic-overlap disease.